Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil

Journal of Neuroimmunology

Volumn 201-202, Issue C, 2008, Pages 111-120

  Janssen, Sofie P M ^a   Phernambucq, Marko ^a   Martinez Martinez, Pilar ^a   De Baets, Marc H ^a,b   Losen, Mario ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Acetylcholine receptor; Immunosuppression; Myasthenia gravis; Mycophenolate mofetil; Neuromuscular junction

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; TREATMENT RESPONSE;

ACTION POTENTIALS; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; ELECTROMYOGRAPHY; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MUSCLE PROTEINS; MUSCLE, SKELETAL; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; MYCOPHENOLIC ACID; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; STATISTICS, NONPARAMETRIC; TIME FACTORS; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS;

EID: 51849128170     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.05.029     Document Type: Article

References (53)

1. Allison A.C., and Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 (2000) 85-118
2. Blaheta R.A., Leckel K., Wittig B., Zenker D., Oppermann E., Harder S., Scholz M., Weber S., Schuldes H., Encke A., and Markus B.H. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transpl. Immunol. 6 (1998) 251-259
3. Caponnetto C., Rossi E., and Primavera A. Mycophenolate mofetil: a new immunosuppressive approach. Successful treatment in a case of myasthenia gravis associated with incomplete lupus erythematosus syndrome and hepatitis C virus infection. Eur. Neurol. 46 (2001) 53-54
4. Chaudhry V., Cornblath D.R., Griffin J.W., O'Brien R., and Drachman D.B. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56 (2001) 94-96
5. Ciafaloni E. Mycophenolate mofetil and myasthenia gravis. Lupus 14 Suppl 1 (2005) s46-49
6. Ciafaloni E., Massey J.M., Tucker-Lipscomb B., and Sanders D.B. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56 (2001) 97-99
7. Cohn R.G., Mirkovich A., Dunlap B., Burton P., Chiu S.H., Eugui E., and Caulfield J.P. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 68 (1999) 411-418
8. De Baets M., and Stassen M.H. The role of antibodies in myasthenia gravis. Ann. N.Y. Acad. Sci. 202 (2002) 5-11
9. De Baets M., Stassen M., Losen M., Zhang X., and Machiels B. Immunoregulation in experimental autoimmune myasthenia gravis-about T cells, antibodies, and endplates. Ann. N.Y. Acad. Sci. 998 (2003) 308-317
10. Derijks L.J., Gilissen L.P., Engels L.G., Bos L.P., Bus P.J., Lohman J.J., Curvers W.L., Van Deventer S.J., Hommes D.W., and Hooymans P.M. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther. Drug. Monit. 26 (2004) 311-318
11. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330 (1994) 1797-1810
12. Durez P., Appelboom T., Pira C., Stordeur P., Vray B., and Goldman M. Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-alpha and upregulation of IL-10 release. Int. J. Immunopharmacol. 21 (1999) 581-587
13. Enk A.H., and Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 350 (1997) 494
14. Eugui E.M., Mirkovich A., and Allison A.C. Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant. Proc. 23 (1991) 15-18
15. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345 (1995) 1321-1325
16. Gajdos P., Chevret S., and Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane. Database. Syst. Rev. (2006) CD002277
17. Garcia-Carrasco M., Escarcega R.O., Fuentes-Alexandro S., Riebeling C., and Cervera R. Therapeutic options in autoimmune myasthenia gravis. Autoimmun. Rev. 6 (2007) 373-378
18. Gibson W.T., and Hayden M.R. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann. N. Y. Acad. Sci. 1110 (2007) 209-221
19. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., Petri M., Gilkeson G.S., Wallace D.J., Weisman M.H., and Appel G.B. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353 (2005) 2219-2228
20. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin. Exp. Rheumatol. 11 Suppl 8 (1993) S117-119
21. Gronseth G.S., and Barohn R.J. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55 (2000) 7-15
22. Gunnarsdottir S., and Elfarra A.A. Glutathione-dependent metabolism of cis-3-(9H-purin-6-ylthio)acrylic acid to yield the chemotherapeutic drug 6-mercaptopurine: evidence for two distinct mechanisms in rats. J. Pharmacol. Exp. Ther. 290 (1999) 950-957
23. Hagberg R.C., Hoyt E.G., Billingham M.E., Sibley R.K., Starnes V.A., and Baldwin J.C. Comparison of cyclosporin A and G with and without azathioprine regarding immunosuppressive efficacy, toxicity, and pharmacokinetics in Lewis rats. J. Heart. Transplant. 7 (1988) 359-369
24. Hampton T. Trials assess myasthenia gravis therapies. Jama 298 (2007) 29-30
25. Hauser R.A., Malek A.R., and Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 51 (1998) 912-913
26. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., and Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7 (2001) 365-368
27. Hoedemaekers A., Graus Y., van Breda Vriesman P., and de Baets M. Age- and sex-related resistance to chronic experimental autoimmune myasthenia gravis (EAMG) in Brown Norway rats. Clin. Exp. Immunol. 107 (1997) 189-197
28. Hoedemaekers A., Bessereau J.L., Graus Y., Guyon T., Changeux J.P., Berrih-Aknin S., van Breda Vriesman P., and De Baets M.H. Role of the target organ in determining susceptibility to experimental autoimmune myasthenia gravis. J. Neuroimmunol. 89 (1998) 131-141
29. Larkin G., and Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 106 (1999) 370-374
30. Lehmann H.C., Hartung H.P., Hetzel G.R., Stuve O., and Kieseier B.C. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch. Neurol. 63 (2006) 1066-1071
31. Lennon V.A., Lindstrom J.M., and Seybold M.E. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 141 (1975) 1365-1375
32. Lim A.K., Donnan G., Chambers B., and Ierino F.L. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity. Intern. Med. J. 37 (2007) 55-59
33. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., and Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26 (1976) 1054-1059
34. Losen M., Stassen M.H., Martinez-Martinez P., Machiels B.M., Duimel H., Frederik P., Veldman H., Wokke J.H., Spaans F., Vincent A., and De Baets M.H. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain 128 (2005) 2327-2337
35. Losen M., Martínez-Martínez P., Phernambucq M., Schuurman J., Parren P.W., and De Baets M.H. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Ann. N.Y. Acad. Sci. 1132 (2008) 174-179
36. Martinez-Martinez P., Losen M., Duimel H., Frederik P., Spaans F., Molenaar P., Vincent A., and De Baets M.H. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. Am. J. Pathol. 170 (2007) 644-657
37. Meriggioli M.N., Ciafaloni E., Al-Hayk K.A., Rowin J., Tucker-Lipscomb B., Massey J.M., and Sanders D.B. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 61 (2003) 1438-1440
38. Meriggioli M.N., Rowin J., Richman J.G., and Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann. N. Y. Acad. Sci. 998 (2003) 494-499
39. Mowzoon N., Sussman A., and Bradley W.G. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J. Neurol. Sci. 185 (2001) 119-122
40. Neurath M.F., Wanitschke R., Peters M., Krummenauer F., Meyer zum Buschenfelde K.H., and Schlaak J.F. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 44 (1999) 625-628
41. Nowack R., Gobel U., Klooker P., Hergesell O., Andrassy K., and van der Woude F.J. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J. Am. Soc. Nephrol. 10 (1999) 1965-1971
42. Palace J., Newsom-Davis J., and Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50 (1998) 1778-1783
43. Patel A.A., Swerlick R.A., and McCall C.O. Azathioprine in dermatology: the past, the present, and the future. J. Am. Acad. Dermatol. 55 (2006) 369-389
44. Prakash K.M., Ratnagopal P., Puvanendran K., and Lo Y.L. Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: the Singapore experience. J. Clin. Neurosci. 14 (2007) 278-281
45. Richman D.P., and Agius M.A. Treatment of autoimmune myasthenia gravis. Neurology 61 (2003) 1652-1661
46. Sanders D.B., Hart I.K., Mantegazza R., Shukla S.S., Siddiqi Z.A., De Baets M.H., Melms A., Nicolle M.W., Solomons N., and Richman D.P. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology (2008) 10.1212/01.wnl.0000312374.95186.cc
47. Schneider-Gold C., Hartung H.P., and Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle. Nerve. 34 (2006) 284-291
48. Schneider C., Gold R., Reiners K., and Toyka K.V. Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur. Neurol. 46 (2001) 79-82
49. Seybold M.E., Lambert E.H., Lennon V.A., and Lindstrom J.M. Experimental autoimmune myasthenia: clinical, neurophysiologic, and pharmacologic aspects. Ann. N. Y. Acad. Sci. 274 (1976) 275-282
50. Sieb J.P. Myasthenia gravis: emerging new therapy options. Curr. Opin. Pharmacol. 5 (2005) 303-307
51. The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology (2008) 10.1212/01.wnl.0000312374.95186.cc
52. Tran G.T., Carter N., and Hodgkinson S.J. Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis. Int. Immunopharmacol. 1 (2001) 1709-1723
53. Zandman-Goddard G., and Shoenfeld Y. Mycophenolate mofetil in animal models of autoimmune disease. Lupus 14 Suppl 1 (2005) s12-16